Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naive in Penta-Relapsed Refractory Multiple Myeloma (RRMM)

被引：1
|
作者：
Mammadzadeh, Aytaj [1 ]
Peng, Fulei [2 ]
Atrash, Shebli [3 ,4 ]
Hashmi, Hamza [3 ,5 ]
Mohan, Meera [3 ,6 ]
Alkharabsheh, Omar [3 ,7 ]
Afrough, Aimaz [3 ,8 ]
Cui, Wei [3 ,9 ]
Mahmoudjafari, Zahra [3 ,10 ]
Abdallah, Al-Ola [11 ,12 ]
机构：
[1] Azerbaijan Med Univ, Dept Internal Med, Baku, Azerbaijan
[2] Mercy St Louis Hosp, Dept Internal Med, St Louis, MO USA
[3] US Myeloma Res Innovat Res Collaborat USMIRC, Westwood, KS USA
[4] Atrium Hlth, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA
[5] Med Univ South Carolina, Dept Hematol Med Oncol, Charleston, SC 29425 USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Univ S Alabama, Mitchell Canc Inst, Div Hematol Oncol, Mobile, AL USA
[8] UT Southwestern Med Ctr, Div Hematol Malignancies & Cellular Therapy, Dept Internal Med, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA
[9] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[10] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS 66103 USA
[11] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Westwood, KS USA
[12] US Myeloma Innovat Res Collaborat USMIRC, Westwood, KS USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-165762
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4277 / 4278
页数：2
相关论文
共 50 条
  • [41] Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma
    Chen, Dongjian
    Wang, Xiaoxiang
    Chen, Zhi
    Jiang, Songfu
    Jiang, Hua
    Fu, Weijun
    Xiang, Fang
    Sun, Xuedong
    Du, Juan
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (12) : E478 - E481
  • [42] Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
    Ahsan, Aarif
    Mantis, Christine
    Luo, Xizhi
    Zhang, Catherine C.
    Valdes, Cesar Rodriguez
    Voorhees, Peter M.
    D'Souza, Anita
    Chung, Alfred
    Tuchman, Sascha
    Safah, Hana
    Mckay, John T.
    Weisel, Katja C.
    Teipel, Raphael
    Korde, Neha
    Vij, Ravi
    Kumar, Shaji
    Bueno, Orlando Felix
    Pothacamury, Rajvineeth Kumar
    Talati, Chetasi
    Ross, Jeremy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).
    Bahlis, Nizar J.
    Raje, Noopur S.
    Costello, Caitlin
    Dholaria, Bhagirathbhai R.
    Solh, Melhem M.
    Levy, Moshe Y.
    Tomasson, Michael H.
    Dube, Harman
    Liu, Feng
    Liao, Kai Hsin
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward Michael
    Trudel, Suzanne
    Jakubowiak, Andrzej J.
    Chu, Michael P.
    Gasparetto, Cristina
    Dalovisio, Andrew
    Sebag, Michael
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
    Berdeja, Jesus G.
    Madduri, Deepu
    Usmani, Saad Zafar
    Singh, Indrajeet
    Zudaire, Enrique
    Yeh, Tzu-Min
    Allred, Alicia J.
    Olyslager, Yunsi
    Banerjee, Arnob
    Goldberg, Jenna D.
    Schecter, Jordan
    Geng, Dong
    Wu, Xiaoling
    Carrasco-Alfonso, Marlene
    Rizvi, Syed
    Fan, Frank
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy
    Van Oekelen, Oliver
    Mouhieddine, Tarek
    Pan, Darren
    Metzger, Megan
    Agte, Sarita
    Aleman, Adolfo
    Melnekoff, David
    Lancman, Guido
    Lagana, Alessandro
    Richard, Shambavi
    Sanchez, Larysa
    Richter, Joshua
    Cho, Hearn Jay
    Chari, Ajai
    Jagannath, Sundar
    Parekh, Samir
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S38 - S38
  • [46] Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Raje, Noopur S.
    Jakubowiak, Andrzej
    Gasparetto, Cristina
    Cornell, Robert F.
    Krupka, Heike I.
    Navarro, Daniel
    Forgie, Alison J.
    Udata, Chandrasekhar
    Basu, Cynthia
    Chou, Jeffrey
    Leung, Abraham
    Lesokhin, Alexander M.
    BLOOD, 2019, 134
  • [47] Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy
    Grajales-Cruz, Ariel F.
    Castaneda, Omar
    Hansen, Doris K.
    Vazquez-Martinez, Mariola A.
    Blue, Brandon
    Khadka, Sushmita
    Liu, Hien
    Ochoa-Bayona, Jose L.
    Freeman, Ciara Louise L.
    Locke, Frederick L.
    Nishihori, Taiga
    Shain, Kenneth
    Baz, Rachid
    Alsina, Melissa
    BLOOD, 2023, 142
  • [48] Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
    Samer Al Hadidi
    Aniko Szabo
    Jean Esselmann
    Lindsay Hammons
    Munawwar Hussain
    Yetunde Ogunsesan
    Nishanth Thalambedu
    Fatima Khan
    Jaskirat Sethi
    Abhishek Janardan
    Sabarinath Venniyil Radhakrishnan
    Sharmilan Thanendrarajan
    Carolina Schinke
    Binod Dhakal
    Siegfried Janz
    Saurabh Chhabra
    Anita D’Souza
    Maurizio Zangari
    Frits van Rhee
    Meera Mohan
    Bone Marrow Transplantation, 2023, 58 : 443 - 445
  • [49] Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    van de Donk, Niels
    Moreau, Philippe
    Garfall, Alfred
    Bhutani, Manisha
    Oriol, Albert
    Nooka, Ajay
    Martin, Thomas
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez Lopez, Joaquin
    Krishnan, Amrita
    Delforge, Michel
    Trancucci, Danielle
    Verona, Raluca
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S478
  • [50] Long-term follow-up from MajesTEC-1 of Teclistamab, a B-cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Donk, Van De N. W.
    Moreau, P.
    Garfall, A. L.
    Bhutani, M.
    Oriol, A.
    Nooka, A. K.
    Martin, T. G.
    Rosinol, L.
    Mateos, M. -V.
    Bahlis, N.
    Popat, R.
    Besemer, B.
    Lopez, Martinez J.
    Krishnan, A.
    Delforge, M.
    Trancucci, D.
    Verona, R., I
    Stephenson, T.
    Chastain, K.
    Sidana, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 124 - 124
12345